Form 4: Tarsus Director Sells Over $1.8M in Stock

Tarsus Pharmaceuticals Director William J. Link, PhD, reported the sale of 22,946 shares of common stock totaling approximately $1.86 million on December 15, 2025.

Summary

• Dr. William J. Link, a Director of Tarsus Pharmaceuticals, Inc., reported the sale of 22,946 shares of common stock on December 15, 2025.
• The sales were executed at weighted average prices ranging from $80.71 to $82.39 per share.
• A total of 12,500 shares were sold directly by Dr. Link.
• An additional 10,446 shares were sold indirectly through Link Family Enterprise, LP, where Dr. Link is the controlling member.
• The total value of these transactions is approximately $1.86 million.
• Following these transactions, Dr. Link directly beneficially owns 128,832 shares of Tarsus Pharmaceuticals common stock and indirectly owns 0 shares through Link Family Enterprise, LP.
• Some of the direct sales (12,500 shares) were made pursuant to a Rule 10b5-1 trading plan adopted on September 8, 2025.
• The indirect sales (10,446 shares) were not effected under a Rule 10b5-1 trading plan.

Sentiment

Score: 4

Explanation: The sale of a substantial number of shares by a director, totaling approximately $1.86 million, generally indicates a neutral to slightly negative sentiment from the insider regarding the stock's immediate future appreciation. While some sales were pre-planned, the overall volume of selling by a key insider can be a yellow flag for investors.

Positives

• The sales occurred at relatively high prices, with weighted averages ranging from $80.71 to $82.39 per share.
• A portion of the sales (12,500 shares) were pre-planned under a Rule 10b5-1 trading plan, indicating a structured approach to managing equity holdings rather than an immediate reaction to new information.

Negatives

• The sale of a significant number of shares (22,946 shares) by a director can be perceived negatively by investors, potentially signaling that the insider believes the stock is fully valued or that future growth prospects may be limited.
• A portion of the sales (10,446 shares) were not conducted under a pre-arranged 10b5-1 plan, which might suggest a more discretionary decision to sell.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing, an insider transaction report, does not provide specific industry context or relate to broader industry trends or competitors beyond the reported stock sales by a director.

Related Party Transactions

• The indirect sale of 10,446 shares by Link Family Enterprise, LP, where Dr. William J. Link is the controlling member, represents a transaction involving a related entity.

Stakeholder Impact

• Shareholders may interpret the insider selling as a signal that the stock's current valuation is high or that future growth prospects are not as strong, potentially leading to negative sentiment or a re-evaluation of their investment thesis.
• Company Management: While routine for diversification or tax planning, significant insider sales can sometimes raise questions about management's confidence in the company's near-term outlook.

Key Dates

Recommendation

The sale of a substantial number of shares by a director, even partially under a 10b5-1 plan, suggests that the insider may view the current stock price as a good exit point. While not an outright negative, it doesn't signal strong conviction for significant future upside, leading to a 'hold' recommendation for existing investors to re-evaluate their positions.

Keywords

Tarsus Pharmaceuticals, TARS, insider trading, stock sale, Form 4, William J. Link, director, equity